• AnaptysBio, Inc. (NASDAQ:ANAB) is struggling with a ROIC of -26.40% against a WACC of 12.23%, indicating poor capital utilization.
• Similar challenges are observed in Deciphera Pharmaceuticals, Inc. (DCPH), Crinetics Pharmaceuticals, Inc. (CRNX), Rhythm Pharmaceuticals, Inc. (RYTM), and Kura Oncology, Inc. (KURA) with negative ROIC to WACC ratios, highlighting inefficiencies in capital utilization.
• CytomX Therapeutics, Inc. (CTMX) showcases effective capital utilization with a ROIC of 66.72% and a WACC of 13.54%, indicating strong growth potential.

AnaptysBio, Inc. (NASDAQ:ANAB) is a biotechnology company focused on developing antibody therapeutics for inflammation and immuno-oncology. The company is currently facing challenges in generating returns on its invested capital. AnaptysBio's ROIC is -26.40%, which is significantly lower than its WACC of 12.23%. This indicates that the company is not effectively using its capital to generate returns.

In comparison, Deciphera Pharmaceuticals, Inc. (DCPH) also shows a negative ROIC of -29.48% against a WACC of 5.15%. This results in a ROIC to WACC ratio of -5.72, suggesting that Deciphera is facing similar challenges in capital efficiency. Crinetics Pharmaceuticals, Inc. (CRNX) follows closely with a ROIC of -28.74% and a WACC of 5.29%, leading to a ROIC to WACC ratio of -5.44.

Rhythm Pharmaceuticals, Inc. (RYTM) presents a more concerning picture with a ROIC of -62.80% and a WACC of 15.33%. This results in a ROIC to WACC ratio of -4.10, indicating significant inefficiencies in capital utilization. Kura Oncology, Inc. (KURA) also struggles with a ROIC of -31.40% and a WACC of 5.98%, resulting in a ROIC to WACC ratio of -5.26.

CytomX Therapeutics, Inc. (CTMX) stands out positively with a ROIC of 66.72% and a WACC of 13.54%. This results in a ROIC to WACC ratio of 4.93, highlighting its effective capital utilization. CytomX's ability to generate returns that exceed its cost of capital sets it apart from its peers, showcasing its strong growth potential.